Crystalline Naloxol-Peg Conjugate

Patent No. EP2621496 (titled "Crystalline Naloxol-Peg Conjugate") was filed by Astrazeneca on Sep 29, 2011. The application was issued on Dec 12, 2018.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STADA ARZNEIMITTELSep 16, 2016KERNEBECK
ABG PATENTESSep 16, 2016ABG PATENTES
GENERICS UKSep 16, 2016COOKE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2621496

ASTRAZENECA
Application Number
EP11829686A
Filing Date
Sep 29, 2011
Status
Patent Maintained As Amended
Nov 9, 2018
Publication Date
Dec 12, 2018